Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

BACKGROUND: The phase II J003 (N = 169) and phase III RECOURSE (N = 800) trials demonstrated a significant improvement in survival with trifluridine (FTD)/tipiracil (TPI) versus placebo in patients with refractory metastatic colorectal cancer. This post hoc analysis investigated pharmacokinetic data...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, T., Cleary, J. M., Van Cutsem, E., Mayer, R. J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., Garcia-Carbonero, R., Komatsu, Y., Baba, H., Argilés, G., Tsuji, A., Sobrero, A., Yamaguchi, K., Peeters, M., Muro, K., Zaniboni, A., Sugimoto, N., Shimada, Y., Tsuji, Y., Hochster, H. S., Moriwaki, T., Tran, B., Esaki, T., Hamada, C., Tanase, T., Benedetti, F., Makris, L., Yamashita, F., Lenz, H.-J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491979/
https://www.ncbi.nlm.nih.gov/pubmed/31912801
http://dx.doi.org/10.1016/j.annonc.2019.10.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491979/
https://www.ncbi.nlm.nih.gov/pubmed/31912801
http://dx.doi.org/10.1016/j.annonc.2019.10.005

Ejemplares similares